The Novel Long-Acting Peptide S6-FA Attenuates Liver Fibrosis In Vitro and In Vivo.
Ontology highlight
ABSTRACT: Liver fibrosis can progress to cirrhosis and hepatocellular carcinoma. Currently, there is no effective drug for liver fibrosis. The peptide 6 (T6) is an endogenous peptide derived from human intrauterine adhesion tissues and has antifibrotic potential. Here, to improve the long-term efficacy and activity of T6, we conducted the rational modified of T6 through studying structure-activity, and synthesized a series of analogues. Among them, S6 and S6-FA exhibited optimal antihepatic fibrosis activity, and S6-FA had a stronger long-acting effect than T6 and S6. The two analogues inhibited the expression of α-SMA and Collagen 1 in TGF-β-induced LX2 cells model and CCl4-induced mouse model of liver fibrosis. Besides, we discovered that S6 and S6-FA remarkably reduced the AST and ALT
SUBMITTER: Li M
PROVIDER: S-EPMC11904669 | biostudies-literature | 2025 Mar
REPOSITORIES: biostudies-literature
ACCESS DATA